Literature DB >> 11052214

Levodopa motor complications in Parkinson's disease.

J A Obeso1, C W Olanow, J G Nutt.   

Abstract

Parkinson's disease (PD) is an age-related neurodegenerative disorder with an average onset age of 60 years. In the United States, approximately one million persons suffer from PD, and there are 60,000 newly diagnosed cases every year. The estimated cost of PD to society is $27 billion per year. Based on United States Census Bureau projections, it is estimated that the frequency of PD will increase fourfold by the year 2040, making it an even larger burden on patients, their families and society.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11052214     DOI: 10.1016/s1471-1931(00)00031-8

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  107 in total

Review 1.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

Review 2.  Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.

Authors:  Yoland Smith; Thomas Wichmann; Stewart A Factor; Mahlon R DeLong
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

3.  Striatal overexpression of DeltaFosB reproduces chronic levodopa-induced involuntary movements.

Authors:  Xuebing Cao; Toru Yasuda; Subramaniam Uthayathas; Ray L Watts; M Maral Mouradian; Hideki Mochizuki; Stella M Papa
Journal:  J Neurosci       Date:  2010-05-26       Impact factor: 6.167

Review 4.  Imaging in cell-based therapy for neurodegenerative diseases.

Authors:  Deniz Kirik; Nathalie Breysse; Tomas Björklund; Laurent Besret; Philippe Hantraye
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12       Impact factor: 9.236

5.  Improvement of impulse control disorders associated with levodopa-carbidopa intestinal gel treatment in advanced Parkinson's disease.

Authors:  Maria Jose Catalan; Jose Antonio Molina-Arjona; Pablo Mir; Esther Cubo; Jose Matias Arbelo; Pablo Martinez-Martin
Journal:  J Neurol       Date:  2018-03-20       Impact factor: 4.849

6.  Rebalance of striatal NMDA/AMPA receptor ratio underlies the reduced emergence of dyskinesia during D2-like dopamine agonist treatment in experimental Parkinson's disease.

Authors:  Vincenza Bagetta; Carmelo Sgobio; Valentina Pendolino; Giulia Del Papa; Alessandro Tozzi; Veronica Ghiglieri; Carmela Giampà; Elisa Zianni; Fabrizio Gardoni; Paolo Calabresi; Barbara Picconi
Journal:  J Neurosci       Date:  2012-12-05       Impact factor: 6.167

7.  α4β2 Nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats.

Authors:  Maryka Quik; Carla Campos; Tanuja Bordia; Jon-Paul Strachan; Jenny Zhang; J Michael McIntosh; Sharon Letchworth; Kristen Jordan
Journal:  Neuropharmacology       Date:  2013-04-12       Impact factor: 5.250

8.  The Impact of Deep Brain Stimulation for Parkinson's Disease on Couple Satisfaction: An 18-Month Longitudinal Study.

Authors:  Marc Baertschi; Nicolas Favez; João Flores Alves Dos Santos; Michalina Radomska; François Herrmann; Pierre Burkhard; Alessandra Canuto; Kerstin Weber
Journal:  J Clin Psychol Med Settings       Date:  2019-12

Review 9.  Potential of transdermal drug delivery in Parkinson's disease.

Authors:  Ronald F Pfeiffer
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

10.  Persistent increase in olfactory type G-protein alpha subunit levels may underlie D1 receptor functional hypersensitivity in Parkinson disease.

Authors:  Jean-Christophe Corvol; Marie-Paule Muriel; Emmanuel Valjent; Jean Féger; Naïma Hanoun; Jean-Antoine Girault; Etienne C Hirsch; Denis Hervé
Journal:  J Neurosci       Date:  2004-08-04       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.